Reply to: Population genetic considerations regarding the interpretation of within-patient SARS-CoV-2 polymorphism data
Nat Commun
.
2024 Apr 16;15(1):3239.
doi: 10.1038/s41467-024-46262-3.
Authors
Chase W Nelson
1
2
,
Leo L M Poon
3
4
5
,
Haogao Gu
6
Affiliations
1
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, 20850, USA.
2
Institute for Comparative Genomics, American Museum of Natural History, New York, NY, 10024, USA.
3
School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
[email protected]
.
4
Centre for Immunology & Infection, Hong Kong Science and Technology Park, Hong Kong SAR, China.
[email protected]
.
5
HKU- Pasteur Research Pole, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
[email protected]
.
6
School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
PMID:
38627383
PMCID:
PMC11021549
DOI:
10.1038/s41467-024-46262-3
No abstract available
Publication types
Letter
MeSH terms
COVID-19*
Genetics, Population
Humans
Polymorphism, Genetic
SARS-CoV-2* / genetics
Grants and funding
COVID190205/Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund (HMRF)
T11-705/21-N/Research Grants Council, University Grants Committee (RGC, UGC)
PDFS2324-7S03/Research Grants Council, University Grants Committee (RGC, UGC)
DESC0014664/U.S. Department of Energy (DOE)